Sign inJoin waitlistJoin the waitlist

Margaret Gatti-Mays

Deputy Director, Division of Medical Oncology · Ohio State University Hospital

Credentials: · · · · · · ·

History

Breast Oncology Section · Ohio State University Hospital
Present
Ohio State University Hospital
Present

Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2014–2017
MedStar Georgetown University Hospital
2011–2014
Georgetown University School of Medicine
2007–2011

Research

Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease
Value in Health · 2009 · 357 citations
Current Landscape of Immunotherapy in Breast Cancer: A Review
JAMA Oncology · 2019 · 317 citations
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Journal for ImmunoTherapy of Cancer · 2019 · 238 citations

Daniel Stover
29 papers
Robert Wesolowski
26 papers
Sagar Sardesai
24 papers
Nicole Williams
23 papers
AD
Ashley Davenport
19 papers · 1 as a fellow
James Gulley
16 papers
KJ
Kai Johnson
16 papers · 3 as a fellow
PS
Preeti Sudheendra
15 papers
Dionisia Quiroga
13 papers
Matthew Cherian
13 papers
Julius Strauss
11 papers
BR
Bhuvaneswari Ramaswamy
9 papers

Grants

Breast and Other Carcinoma Clinical Trials Using Immunotherapies
National Cancer Institute · ZIA
Contact PI · $1.1M · Division of Basic Sciences - Nci

Clinical trials

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Principal investigator · Recruiting · Phase 1, Phase 2
Margaret Gatti-Mays
2024–2027
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Marengo Therapeutics, Inc.
2025–2028
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2033
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Site PI · Recruiting · Phase 2
Dana-Farber Cancer Institute
2020–2029